Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

Isabel Poschke, Marta Faryna, Frank Bergmann, Michael Flossdorf, Claudia Lauenstein, Jennifer Hermes, Ulf Hinz, Thomas Hank, Roland Ehrenberg, Michael Volkmar, Martin Loewer, Hanno Glimm, Thilo Hackert, Martin R. Sprick, Thomas Höfer, Andreas Trumpp, Niels Halama, Jessica C. Hassel, Oliver Strobel, Markus Büchler, Ugur Sahin, Rienk Offringa.

ABSTRACT

Purpose: The devastating prognosis of patients with resectable pancreatic ductal adenocarcinoma (PDA) presents an urgent need for the development of therapeutic strategies targeting disseminated tumor cells. Until now, T-cell therapy has been scarcely pursued in PDA, due to the prevailing view that it represents a poorly immunogenic tumor. Experimental design: We systematically analyzed T-cell infiltrates in tumor biopsies from 127 patients with resectable PDA by means of immunohistochemistry, flow cytometry, T-cell receptor (TCR) deep-sequencing and functional analysis of in vitro expanded T-cell cultures. Parallel studies were performed on tumor-infiltrating lymphocytes (TIL) from 44 patients with metastatic melanoma.

Results: Prominent T-cell infiltrates, as well as tertiary lymphoid structures harboring proliferating T-cells, were detected in the vast majority of biopsies from PDA patients. The notion that the tumor is a site of local T-cell expansion was strengthened by TCR deep-sequencing, revealing that the T-cell repertoire in the tumor is dominated by highly frequent CDR3 sequences that can be up to 10,000-fold enriched in tumor as compared to peripheral blood. In fact, TCR repertoire composition in PDA resembled that in melanoma. Moreover, in vitro expansion of TILs was equally efficient for PDA and melanoma, resulting in T-cell cultures displaying HLA class I-restricted reactivity against autologous tumor cells.

Conclusions: The tumor-infiltrating T-cell response in PDA shows striking similarity to that in melanoma, where adoptive T-cell therapy has significant therapeutic impact. Our findings indicate that T-cell-based therapies may be used to counter disease recurrence in patients with resectable PDA.

Introduction

Over the past 5 y, cancer immunotherapy has come of age with the FDA approval of checkpoint inhibitor antibodies targeting the T-cell inhibitory receptors CTLA-4 and PD-1, supported by striking clinical results in melanoma and lung cancer. Nevertheless, unleashing antitumor T-cell immunity by blocking negative signals does not succeed in all cancer types, suggesting that alternative approaches are still needed.

One example in this respect is pancreatic ductal adenocarcinoma (PDA), the most common type of pancreatic cancer. At time of diagnosis, approximately 80% of patients are deemed non-resectable due to local tumor spread and/or the detection of macroscopically visible metastases. In spite of recently improved chemotherapeutic regimens, e.g., involving Nab-Paclitaxel or FOLFIRINOX, the median overall survival time of these patients is a mere 9–11 mo. Approximately 20–30% of patients diagnosed with PDA have a better prognosis, because their tumor is primary resectable, or secondary resectable after neo-adjuvant chemo/chemo-radiotherapy. Nevertheless, the median survival of these patients is still only 20–24 mo, due to the high recurrence rate, amounting to 70% within 2 y.

Unfortunately, initial trials with checkpoint inhibitors, in particular PD-1-blocking antibodies, did not show a promising outcome in PDA patients, in spite of evidence that these tumors express significant levels of PD-L1. This has strengthened the longstanding notion that PDA is a poorly immunogenic, “cold” tumor. Approaches to elicit antitumor immunity in PDA by means of vaccination or agonist anti-CD40 immunostimulatory antibodies appear to be more successful.

Even though these clinical trials have not yet
shown striking clinical impact, it is evident from these studies that, amidst the hostile microenvironment of pancreatic tumors, T-cells are present that could be mobilized when stimulated properly.

Being confronted with the devastating recurrence rate of PDA patients and based on our experience in charting the T-cell response in “more immunogenic” tumors like melanoma, colorectal cancer and HPV16 cervical cancer, we set off to systematically analyze the T-cell infiltrate in biopsies from primary PDA tumors, using tumor-infiltrating lymphocytes (TILs) from metastatic melanoma as our benchmark. Interestingly, we found that most PDA tumors actually contain significant numbers of T-cells and, along with that, tertiary lymphoid structures in which clonal T-cell expansion takes place. Further phenotypic and functional analysis of these TILs revealed striking similarities with T-cells isolated from melanoma. Taken together, our data indicate that adoptive T-cell therapy using T-cells or tumor-reactive T-cell receptors (TCRs) obtained from the primary tumor may be used to combat disease recurrence in patients with primary resectable PDA.

Materials and methods

Patients

127 patients with resected PDA were analyzed. Details on this patient population are summarized in Table S1. 44 patients with metastatic melanoma served as controls for studies on the in vitro expansion of TIL.

Freshly resectable tumor tissue and blood samples from PDA and melanoma patients were obtained via the European Pancreas Center and the Dermatology Department of Heidelberg University Hospital.

While we aim to obtain TILs, xenografts, tumor cell lines, as well as immunohistochemistry and TCR-, exome- and RNA sequencing data for every patient, this is not always feasible, in particular due to limited amounts of primary tumor material and/or failure of xenograft/cell line or TIL outgrowth. For details on sample handling and the generation of xenografts and cell lines see Supplemental Methods. Numbers of samples tested are indicated for all experiments shown.

Informed written consent was obtained from all participants before sample collection. The study was approved by the local ethics committee and conducted in accordance with the declaration of Helsinki.

In vitro expansion of tumor-infiltrating lymphocytes (TILs)

TIL cultures were established following the “young-TIL” protocol with minor modifications. Briefly, fresh tumor samples were minced into pieces of approximately 1 mm³ and placed at one piece per well in 24-well culture plates containing X-Vivo 15 medium, supplemented with 2% HSA, 1% Pen-Strep, 20 μg/mL Gentamycine, 2.5 μg/mL Fungizone and 6,000 IU/mL IL-2 (Proluken, Novartis Pharma, Nürnberg, Germany). After 24 h, half of the medium was replaced with fresh, IL-2-containing medium. Plates were visually monitored every few days and cells were split at approximately 80% confluence. On day 14 of culture all wells containing expanding cells were harvested, pooled, analyzed and a sample of cells was subjected to a rapid expansion protocol: 0.1 × 10⁶ pre-expanded TILs were added to 3 × 10⁷ million feeder cells, consisting of peripheral blood mononuclear cells (PBMC) from three different donors, irradiated at 40 Gy. Cultures were set up in standing T25 flasks in 25 mL of X-Vivo 15 medium supplemented with 2% human AB-serum (Sigma-Aldrich, St. Louis, USA), 1% PenStrep and 30 ng/mL OKT-3 (eBioscience, San Diego, USA). After 24 h, 300 IU/mL IL-2 were added to the cultures. After 5 d, half the medium was exchanged for fresh IL-2-containing medium without OKT-3. After day 5, cultures were split upon visual inspection and harvested after 2 weeks of culture. Expanded TILs were analyzed and cryopreserved (in 90% human AB-Serum + 10% DMSO, using a CoolCell controlled rate freezing device (BioCision, San Rafael, USA)) for further analysis.

Immunohistochemistry (IHC) and whole slide imaging

Immunohistochemistry was performed on cryosections. Details on the general staining procedure and antibody-specific protocols are found in Supplemental Methods and Table S2, respectively. Stained tissue sections were visualized using a computerized image analysis system with a dedicated analysis software (VIS software suite, Visiopharm, Denmark).

Prior to image analysis tumor areas were defined by a pathologist and only samples with ≥50 % of tumor area were analyzed. Full tissue sections were analyzed and all evaluable tumor area on the slide was used for quantification. The number of positively stained cells per mm² of tumor was counted.

RNA extraction and T-cell receptor (TCR) sequencing

Cryopreserved tumor pieces were thawed, homogenized using a pestle and total RNA was extracted using the RNeasy Mini Kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany).

Blood samples collected in PaxGene tubes or EDTA-tubes were extracted using Paxgene Blood RNA (Pre AnalytiX GmbH, Hilden, Germany) and RiboPure RNA Purification Kit blood (Thermo Fisher Scientific, Waltham, USA), respectively, according to the manufactures instructions. RNA was quantified using a Nanodrop 8000 (Thermo Fisher Scientific, Waltham, USA) and/or a Qubit (Life Technologies, Carlsbad USA) and RNA quality was measured on a Bioanalyzer 2100 (Agilent, Santa Clara, USA).

For analysis of the TCR repertoire, 250 ng total RNA was reverse transcribed using a template switch oligo (TSO), TRAC- and TRBC- gene-specific primers (RT-TRAC, RT-TRBC), and RevertAid H Minus Reverse Transcriptase (Thermo Scientific, Waltham, USA) in buffer enriched to 6 mM Mg²⁺. For primer sequences, please refer to Table S3. Incubation time was 90 min at 42°C followed by 15 min at 72°C. One-sixth of cDNA was then amplified using PfuUltra Hotstart DNA Polymerase (Agilent, Santa Clara, USA) with the PCR program: 2 min at 95°C, 20 cycles of 30 s at 94°C, 30 s at 68°C and 45 s at 72°C, followed by 6 min at 72°C (primers: PCR1-TS, PCR1-TRAC and PCR1-TRBC). PCR products were purified with beads (Beckman Coulter, Danvers, USA) and one-third of the purified product was subjected to further
amplification: 2 min at 95°C, 25 cycles of 30 s at 94°C, 30 s at 65°C, 45 s at 72°C, followed by 6 min at 72°C (primers: PCR2-TS, PCR2-TRAC, PCR2-TRBC1 and PCR2-TRBC2). Final PCR product was size-selected using gel electrophoresis, purified with QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany), subjected to library preparation using TruSeq Nano DNA LT Sample Preparation Kit (Illumina, San Diego, USA) and sequenced using MiSeq v3 600 cycle Reagent Kit (Illumina, San Diego, USA). The average sequencing depth was \( \approx 10^6 \) reads/sample. TCR sequences were identified within raw data sets, translated into amino acids sequences and then divided into V, CDR3 and J regions. V and J genes were then annotated, sets, translated into amino acids sequences and then divided into V, CDR3 and J regions. V and J genes were then annotated, sequence counts for individual regions as well as for V-CDR3-J patterns were calculated, and sequence frequencies were calculated using the Fisher’s exact test and the Mann–Whitney-U-test. Survival analysis was performed using the Kaplan–Meier estimate and the log-rank test was used to compare survival curves statistically. For multivariate survival analysis, the Cox proportional hazards model was used to compute hazard ratios and its 95% confidence interval. Two-sided \( p \)-values <0.05 were considered statistically significant and in the figures are indicated as \( * p < 0.05, ** p < 0.01 \) and \( *** p < 0.001 \).

**Results**

**T-cell infiltration and evidence of in situ clonal T-cell expansion in PDA**

PDA tumors are generally characterized by a strong desmoplastic reaction and abundant stroma that can constitute up to 70% of the tumor mass.\(^{18,19}\) Our analyses were therefore performed on whole sections of tumor tissue by means of a high-resolution automated microscopy-based procedure that allows accurate enumeration of immune cells in heterogeneous tumors and in immune cell conglomerates.\(^{13,17}\) Representative examples of our findings are shown in Fig. 1A. While approximately 25% of the tumors (18/72 analyzed) are sparsely infiltrated with CD3\(^+\) T-cells (mean number of CD3\(^+\) cells <100/mm\(^2\)), the majority of samples showed intermediate (100–300 CD3\(^+\) cells/mm\(^2\); 32/72 = 44\% of samples) to high (>300 CD3\(^+\) cells/mm\(^2\); 22/72 = 31\% of samples) numbers of infiltrating T-cells (Fig. 1C). The mean number of CD3\(^+\) cells/mm\(^2\) was 276 ± 288. The vast desmoplastic parts of PDA tumors were typically devoid of T-cells (Fig. S1).

The infiltration by major T-cell subtypes (CD8\(^+\) cytoxic and FoxP3\(^+\) regulatory T-cells) was examined on serial sections as shown in Fig. 1B. Staining for CD4\(^+\) was not included in our evaluation, because it is known to also detect myeloid cell subsets. The data summary in Fig. 1D shows that CD8\(^+\) T-cells and/or FoxP3\(^+\) T-cells dominate the T-cell infiltrate in a subset of tumors, but not in most cases, and thus suggests that CD4\(^+\) responder T-cells represent the major fraction of CD3\(^+\) T-cells in PDA samples. During the evaluation of our tumor sections, we noted that the majority of samples (78\%) contained multiple dense aggregates of lymphocytes that were dispersed throughout the tissue (exemplified in Fig. 2A). Detailed immunohistochemistry revealed that these conglomerates displayed all hallmarks of ectopic, tertiary lymphoid structures (TLS), in particular T- and B-cell areas with respective co-localization of myeloid and follicular dendritic cells (DC), as well as presence of high-endothelial venules (Figs. S2A and B). Because TLS are known to exert functions similar to secondary lymphoid organs, and contain professional antigen-presenting cells, we hypothesized that the TLS found in PDA tumors might be sites of T-cell activation and proliferation. Concordantly, we observed clusters of Ki-67 positive cells within TLS, indicative of ongoing cell division (Figs. S2C D). In order to substantiate this finding, we also

**Flow cytometry**

Multiparametric flow cytometry was applied to allow characterization of cellular phenotype. Antibody details are provided in Table S4 and staining procedures are detailed in Supplemental Methods. Cells were analyzed using a Fortessa flow cytometer (BD Biosciences, San Jose, CA) and FlowJoX analysis software (Treestar, Ashland, USA).

**Enzyme-linked immunospot (Elispot) assays**

Antitumor reactivity of expanded TILs against autologous tumor cells, passed as in vivo as xenografts or in vitro as cell lines, was assayed using IFNy Elispot (Mabtech, Nacka Strand, Sweden). For blocking experiments, tumor targets were pre-incubated with W6/32 antibody (BioLegend, San Diego, USA). For details on the experimental procedure, see Supplemental Methods. A response was considered positive if wells containing TIL + autologous target had significantly higher spot counts than control wells containing TILs alone.

**Statistical methods**

Statistical analysis was performed using Graph Pad Prism software and SAS software (Release 9.4, SAS-institute, Cary, USA). Differences between groups or experimental conditions were determined using parametric two-tailed t-tests (paired or unpaired, as appropriate). Correlations between TLS-positive and -negative patients and clinical or pathological findings were analyzed using the Fisher’s exact test and the Cox proportional hazards model was used to compute hazard ratios and its 95% confidence interval. Two-sided \( p \)-values <0.05 were considered statistically significant and in the figures are indicated as \( * p < 0.05, ** p < 0.01 \) and \( *** p < 0.001 \).
stained with selected antibodies specific for individual TCR-β-chain V-gene families and found that TLS within a single tumor greatly differed with respect to the numbers of T-cells expressing a given Vβ. In the example shown in Figs. 2B and C, Vβ2-positive T-cells were densely packed in only one of the 15 TLS found in this section, while being more diffusely distributed in other TLS and throughout the tumor. Fig. S3 shows further examples of clustered Vβ2-positive T-cells in TLS that are likely the result of local clonal T-cell expansion. Similar results were obtained using antibodies detecting other Vβ families, although the visualization was more challenging due to lower usage of most of these V-genes in the total T-cell repertoire and/or lesser quality of the primary antibody (data not shown).

Taken together, our immunohistochemistry data suggests that the CD3+ T-cell infiltration found in many of the PDA tumor biopsies is not merely a result of the migration of activated T-cells into the chronically inflamed tumor microenvironment, but also—at least in part—a consequence of local clonal T-cell expansion. Evaluation of the immune infiltrate in the context of post-surgery patient follow-up revealed a significant association between detection of TLS in the resected primary tumors and overall survival (Fig. S4). No correlations of TLS positivity with other clinical or pathological findings were found (Table S1). In line with this, multivariate Cox-regression analysis confirmed the presence of TLS as an independent prognostic factor for prolonged survival (Table S5). Similar analyses on basis of intra-tumoral CD3+, CD8+ and FoxP3+ T-cells, as determined by immunohistochemistry and flow cytometry, did not result in statistically significant correlations with patient survival.

Figure 1. Immune infiltration patterns in primary resectable PDA. (A) Representative examples of PDA tumors showing low (left), intermediate (middle) or high (right) infiltration of CD3+ T-cells; scale bars denote 250 μm; data is representative of 72 patients analyzed. (B) Serial sections of a PDA tumor stained for total CD3+ T-cells (left), CD8+ cytotoxic T-cells (middle) and FoxP3+ regulatory T-cells (right); scale bars denote 250 μm. (C) Proportion of patients (n = 72) displaying low, intermediate or high CD3+ T-cell infiltration (mean CD3 count/mm² tumor area <100, 100–300 and >300, respectively). (D) Number of CD3+, CD8+ and FoxP3+ T-cells/mm² tumor area in PDA patients (n>60). Notably, tumor area is defined as the total tumor tissue, including the stromal and fibrotic areas, but excluding surrounding normal pancreatic tissue and chronically inflamed tissue areas that are not directly associated with the tumor.
PDA tumors contain highly enriched TCR sequences

We proceeded to systematically compare the TCR repertoire in tumor and blood of patients by means of TCR deep-sequencing. Remarkably, in all cases examined, the 10 most frequent CDR3 sequences in the tumor represent 15–60% of the total number of CDR3-reads, while this percentage is significantly lower in blood samples (Fig. 3A). As shown for two representative PDA patients in Fig. 3B, the largest T-cell clones found in the tumor take up a major part of the infiltrating T-cell repertoire. While abundant CDR3 sequences can also be found in the blood of certain patients (PDA-060 in Fig. 3B; blue bar), their frequency is generally much lower than that of the dominant CDR3 sequences found in the tumor (Fig. 3A and PDA-082 in Fig. 3B). The difference in CDR3 repertoire between tumor and blood is further highlighted in Fig. 3C, in which the detected unique CDR3 sequences are ranked on the horizontal axis on the basis of the number of reads. In essence, these graphs illustrate that the tumor T-cell repertoire is dominated by large clones, represented by frequently detected CDR3 sequences. The blood T-cell repertoire, although also containing larger clones, in addition harbors thousands of small T-cell clones, represented by CDR3 sequences that are detected at very low frequencies. This difference in repertoire diversity is also illustrated by the significantly higher clonality values observed in the TILs as compared to the blood TCR repertoire of PDA patients (Fig. 3D).

The enrichment of selected TCRs in the tumor is vividly illustrated by Fig. 3E, which depicts the relative frequencies in which the top-10 CDR3 sequences from the tumor are found in tumor versus blood. Depending on the TCR sequence, this enrichment can be up to 10,000 fold (mean enrichment ≈3,000 fold). A similar analysis of the top-10 CDR3 sequences in the blood of these patients, in which their relative abundance in blood vs. tumor was compared, confirmed the notion that the TCR repertoires in tumor and blood are clearly distinct (Fig. S5A). Even though large peripheral T-cell clones, most likely representing pathogen-specific T-cell responses, can be detected in the tumor, these do not rank highly in the tumor TCR repertoire. This argues against the possibility that the TIL TCR-repertoire would primarily represent activated T-cells that have been drawn into the inflamed tumor microenvironment and/or would be derived from the blood in the tumor vasculature.

Analysis of the TCR repertoire in tumor and blood samples from patients with metastatic melanoma resulted in data highly similar to those obtained in PDA, both with respect to overall clonal distribution (Fig. S5B) and relative frequencies of top-10 tumor CDR3 sequences in tumor versus blood (Fig. 3F, Fig. S5C). Since the existence of a tumor-reactive TIL repertoire in melanoma has been firmly established, and a prognostic role of the TIL TCR repertoire has recently been characterized, this resemblance between melanoma and PDA further supports the existence...
of an antitumor T-cell response in a majority of patients
with primary resectable PDA.

**PDA TILs display an antigen experienced phenotype**

In parallel to our immunohistochemistry and TCR deep-sequencing efforts, we examined the phenotypes of the TILs derived from freshly dissociated PDA samples by means of flow cytometry (Fig. 4, see Fig. S6A for gating strategies). In accordance with the immunohistochemistry data, flow cytometric analysis revealed a diverse immune infiltrate consisting of lymphocytes and myeloid cells (Figs. S6B and C). Furthermore, discrimination between CD4$^+$ and CD8$^+$ T-cell subsets pointed at an overall dominance of CD4$^+$ over CD8$^+$ cells (Fig. 4A).

Importantly, in the majority of cases, this dominance of CD4$^+$ T-cells does not reflect high levels of CD25$^+$CD127-/lowFoxP$^+$ regulatory T-cells (range 2.4–14.4% of CD4$^+$ cells; Fig. 4B; see also immunohistochemistry data in Fig. 1D), suggesting that most CD4$^+$ cells are conventional responder/helper T-cells.

The majority of CD4$^+$ and CD8$^+$ TILs exhibit a CD45RA$^-$CCR7$^-$ effector memory (Tem) phenotype (Fig. 4C) and low expression of the homing receptor CD62L (Figs. 4D and E), which is consistent with their ability to infiltrate tumor tissue. A large fraction of the T-cells are positive for the inhibitory receptor PD-1, while considerably smaller fractions co-express additional inhibitory receptors including CTLA-4, LAG-3 and TIM-3 (Figs. 4D and E), all markers associated with antigen encounter as well as T-cell exhaustion.

The phenotype of PDA TILs is very similar to that observed for melanoma patients (Fig. S7). Of note, melanoma samples show more balanced CD4$^+$ and CD8$^+$ T-cell frequencies (compare Fig. 4A and Fig. S7A) and a more prominent expression of TIM-3 (Fig. S7E).

**Expanded PDA TILs react against autologous tumor cells**

The striking similarities between PDA and melanoma TILs prompted us to perform in vitro TIL expansions with tumor biopsies from 96 PDA patients using the “young TIL protocol” developed by Rosenberg and colleagues. Both the success rate of establishing TIL cultures (≈80%) and the efficiency of in vitro expansion (mean expansion ≈800-fold; Fig. 5A) were very similar for PDA and melanoma, suggesting that expansion of PDA TILs can be scaled up to clinical needs for adoptive TIL therapy as currently performed for melanoma.

Monitoring of TIL phenotype during the culture period revealed that biopsies with diverse levels of T-cell infiltration consistently produced cultures with high T-cell content toward the end of the expansion phase (Fig. 5B). In line with their initial phenotype and the activatory culture
conditions used, the resulting T-cells predominantly display an effector memory phenotype (Fig. 5C). Importantly, in vitro culture appears to revert the exhausted phenotype observed in freshly isolated TILs, in that PD-1 expression strongly decreased in the course of the culture period (Figs. 5D and E).

Whenever sufficient fresh PDA biopsy material was available, we transplanted histologically validated tumor fragments into NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice with the aim to establish pairs of TILs and patient-derived xenografts. For the majority (17 of 20) of currently available matched TIL/tumor sets, the expanded TILs were found to react to the autologous tumor cells from freshly dissociated xenografts (Fig. 6). For PDA-161, where in addition to the xenograft an autologous tumor cell line was available, the TIL reactivity against both types of target cells was comparable (Fig. 6E). While autologous non-tumor cells (e.g., B-cells) were not available as control targets and the use of non-autologous tumors as controls would not be meaningful due to the occurrence of allo-reactions, TIL reactivity could be effectively inhibited by the addition of pan-HLA class I antibodies in 15 of 17 of responding cultures (Fig. 6F). This blockade is in line with the expectation that only the CD8\(^{+}\) T-cells should react against the HLA class I-positive, class II-negative tumor cells. The expanded TILs only occasionally displayed reactivity against the NK-cell target K562 (Fig. 6C), but also in this case antitumor reactivity was efficiently blocked by anti-HLA antibodies, arguing that cytotoxic T-cell and NK-like activity co-exist in this TIL culture.

**Discussion**

Our study provides converging evidence for the existence of an antitumor T-cell response in a majority of patients with primary resectable PDA. While the detection of significant numbers of T-cells with activated phenotype does not suffice as evidence in this respect, because activated T-cells are capable of infiltrating inflamed tissues such as tumors in an antigen-independent fashion,\(^{24}\) our data clearly point at local encounter of tumor antigens and clonal T-cell expansion in the tumor. One

Figure 4. Phenotype of PDA-infiltrating T-cell subsets. Flow cytometric evaluation of (A) the frequency of CD4\(^{+}\) and CD8\(^{+}\) TILs (n = 46) (B) the frequency of regulatory T-cells in CD4\(^{+}\) TILs (n = 14) (C) the distribution of memory cell subsets (naïve – CD45RA\(^{+}\)/CCR7\(^{-}\); Tcm – CD45RA\(^{-}\)/CCR7\(^{+}\), Tem – CD45RA\(^{-}\)/CCR7\(^{-}\), Temra – CD45RA\(^{-}\)/CCR7\(^{-}\)) within tumor-infiltrating CD4\(^{+}\) (left panel) and CD8\(^{+}\) (right panel) T-cells (n = 38). (D–E) Representative flow cytometry data of two primary PDA TIL isolates (totally ≥ 20 PDA patients were analyzed), showing expression of PD1 on CD4\(^{+}\) and CD4\(^{+}\) T-cells (left panel), as well as co-expression patterns of activation and exhaustion markers on CD4\(^{+}\) (top) and CD8\(^{+}\) (bottom) TILs.
key finding is the detection of TLS in the vast majority of tumors tested, along with the clustering of T-cells expressing Ki-67 and certain V-β chains within these TLS. Moreover, we are the first to show, by means of TCR deep-sequencing, that the T-cell repertoire in PDA tumors is clearly less diverse and distinct from that in the peripheral blood and greatly enriched for certain T-cell clones. The 10 most frequently detected TCR CDR3 sequences in the tumor take up 15–60% of the total

Figure 5. In vitro expansion of PDA-infiltrating lymphocytes. (A) Fold expansion of TIL cultures derived from PDA (n = 86) and melanoma (n = 44) patients during the two-week rapid expansion protocol. (B) Frequency of CD3⁺ TILs before start of culture (ex vivo, primary isolate), after pre-expansion in 24-well plates (day 14) and after rapid expansion (day 28) (n ≥ 45), as measured by flow cytometry. (C) Distribution of memory cell subsets (naive – CD45RA⁺/CCR7⁺; Tcm – CD45RA⁻/CCR7⁺; Tem – CD45RA⁻/CCR7⁻; Temra – CD45RA⁺/CCR7⁻) after expansion in CD4⁺ (left panel) and CD8⁺ (right panel) T-cells (n = 60), measured by flow cytometry. (D) Expression of the negative regulatory marker PD-1 on CD4⁺ (left panel) and CD8⁺ (right panel) T-cells before start of culture (ex vivo), after pre-expansion in 24-well plates (day 14) and after rapid expansion (day 28) shown as percent PD1⁺ cells (n ≥ 19). (E) PD-1 fluorescence in T-cells of a representative culture ex vivo, on day 14 and day 28, measured by flow cytometry.
CDR3 reads, while these sequences are detected at much lower frequencies in the patient’s blood. Parallel analyses of tumor and blood samples from patients with metastatic melanoma rendered a highly similar picture. The similarity between the T-cell response in PDA and melanoma is further substantiated by the fact that in vitro expansion of TILs worked equally efficient in our hands for both indications. Last but not least, most of the expanded PDA TIL cultures demonstrated in vitro MHC-class I-restricted reactivity against autologous tumor cells. In view of these findings, we are now working toward the development of adoptive T-cell therapy for countering the devastating recurrence rate in patients with primary resectable PDA.

While our data provide strong support for in vitro tumor-reactivity of PDA TILs, we would like to note that the frequency of tumor-reactive T-cells in the expanded cultures is rather low (≤1%). Accordingly, our pilot in vivo experiments with two selected TIL preparations did not reveal significant efficacy against autologous PDA xenografts, in spite of good in vivo expansion of the TILs (data not shown). Based on longitudinal analysis of the TIL cultures, we have indications that the TCR repertoire changes significantly during ex vivo expansion, including marked decreases in the frequencies of TCRs that are abundant in tumor samples. Our current data suggest that this could be a more prominent problem with PDA than with melanoma TILs (our unpublished observations). Although TIL culture procedures can be optimized to counter the loss of relevant T-cell clones, e.g., by sorting for PD-1 positive cells and/or application of anti-4-1BB co-stimulatory antibodies during culture, the most effective remedy to this problem likely involves cloning of the dominant TCR-α/β sequences from primary tumor material. Our ongoing attempts in this respect are aimed at identifying tumor-dominant TCR-α/β pairs on basis of TCR deep-sequencing data.

A question of definite interest concerns the nature of the T-cell epitopes recognized by tumor-reactive TILs, and in particular whether, in analogy to T-cells from melanoma, lung cancer and colorectal cancer, a majority of these TILs would be directed against mutanome-encoded neo-epitopes. A counter-indication in this respect is the relatively low number of non-synonymous mutations and indels found in PDA. In line with published reports, we find the number of such mutations for primary resectable PDA in the range of 52±15, with an additional 4–6 indels (data not shown). Nevertheless, it was recently demonstrated that T-cell mediated recognition of mutanome-encoded neo-epitopes can also be identified in tumors with lower mutational load, e.g., colorectal, bile duct and esophageal cancer, and that mutanome-specific T-cell reactivity can be found in both the CD8+ and CD4+ arms of the T-cell.

**Figure 6.** Antitumor reactivity of in vitro expanded PDA TIL. (A–E) Reactivity of in vitro expanded PDA TIL against autologous xenograft tumors (tumor) or a xenograft-derived cell line (tumor line; gray bars) measured by IFNγ Elispot, with or without pre-incubation of the tumor cell targets with pan-HLA-class I binding antibody W6/32 (anti-HLA I). (F) Of the 20 expanded TIL cultures for which autologous tumors were available, 17 displayed antitumor reactivity (black lines), whereas 3 did not show a significantly increased spot-count in response to autologous tumor targets (gray lines). In two responding cultures, no significant reduction of IFNγ production was achieved by pre-incubation with the MHC I blocking antibody (marked with #).
response. Moreover, an increasing number of tumor-associated auto-antigens is found to be expressed by the medullary thymic epithelial cells (mTECs), implying that the high affinity T-cell repertoire targeting many of these antigens has been deleted. However, gene expression by mTEC does not cover the full repertoire of auto-antigens, leaving the possibility that TLS found in PDA tumors target auto-antigens or other tumor-associated antigens. In addition over-expression of mutated p53 is known to elicit CD4+ T-helper and IgG antibody responses against non-mutated parts of the antigen, to which the immune system is not tolerant. Notably, the outcome of one of these studies suggested that TLS could only be observed in tumor samples from patients that underwent whole tumor cell vaccination (GVAX) prior to tumor resection, not in pre-vaccination biopsies or biopsies from control patients, and thereby that the TLS were induced by the vaccination. Based on our data and that of Castino and Hiraoaka, in which TLS were found in 75%, 78% and 100% of non-treated patients, respectively, we propose that in the GVAX study the TLS may have been missed in pre-vaccination and control biopsies due to the smaller size of the tumor sections. In fact, our initial estimate of the fraction of TLS-positive tumors based on analysis of a single tumor section was lower (≈50%). However, by sectioning through the negatively scored tumors, we found TLS in an additional ≈30% of samples, illustrating how easily such features may be overlooked. An interesting aspect in the study by Hiraoaka et al. is the distinction between peritumoral and intra-tumoral TLS, and the association of intra-tumoral TLS with prolonged overall survival, which is in line with Castino et al. and similar findings for other cancers. Evaluation of our own data substantiated the link between presence of TLS and better survival in PDA. The protective effect of TLS is further supported by the higher expression of pro-inflammatory cytokines such as IFNγ, IL-12, IL-6, IL-8 in TLS-positive as compared to TLS-negative tumors.

In conclusion, our data clearly demonstrate that PDA is not an immunologically “cold” tumor, as has been suggested in the context of the failure of checkpoint blockade in this indication. Nevertheless, the average number of non-synonymous mutations in PDA is ≈10-fold lower than in melanoma. In fact, the correlation between the clinical impact of checkpoint blockade and mutational load in melanoma offers a plausible explanation for the failure of this therapeutic approach in PDA. Furthermore, it is evident that the PDA microenvironment in patients with advanced disease poses additional hurdles for effective T-cell therapy, such as the physical barrier represented by the extensive stroma and the large number of myeloid cells in the infiltrate.

Disclosure of potential conflicts of interest

U.S. is a shareholder of BioNTech AG. U.S. and M.F. are employed at the BioNTech Corporation (BioNTech AG and its affiliates) and are inventors of the pending patent application published as WO 2015/059277 in the field of TCR deep-sequencing. The other authors have declared that no conflict of interest exists.

Acknowledgments

We thank the biobanks of the National Center for Tumor Diseases (NCT), Heidelberg and of the European Pancreas Center at Heidelberg University Hospital, especially Esther Soya and Dr Nathalia Giese, for great help with sample collection. For TCR deep-sequencing, we thank Lisa Hebich for excellent technical assistance, Dr Tana Omokoko for valuable comments on data and Dr Michael Blank and Christian Grohmann for software support.

Funding

This work was funded by the K.H. Bauer Foundation (to R.O.), the German National Center for Tumor diseases (to R.O., A.T., M.S.; project HiPo-015), the FP7 framework program of the European Community (to R.O., project acronym IACT; grant 602262 and I.P. project acronym TIPC_TIL_IP), the German Ministry of education and research (BMBF) (to I.P., M.F., O.S. and J.H., project acronym TIL-REP, 01ZY1403A; to M.S., A.T., T.Ha., O.S., project acronyms PANC-STRAT, 01ZX1305B, 01ZX1305C), the Helmholtz pre-clinical comprehensive cancer center (PCCC) (to M.S. and A.T.) and the Dietmar Hopp Foundation (to M.S. and A.T.). The work of M.F. and U.S. has been supported by the Central Innovation Program for SMEs (ZIM) of the Federal Ministry for Economic Affairs and Energy (project EP 131299) and the BioNTech Diagnostics GmbH. Biobanking was supported by the Heidelberger Stiftung Chirurgie, (BMBF grants 01GS08114 and 01ZX1305C) and by the Biomaterial Bank Heidelberg/BMBH (BMBF grant 01EY1101).

References

1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161:205-14; PMID:25860605; http://dx.doi.org/10.1016/j.cell.2015.03.030
2. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.cell.2015.03.001
3. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Fries H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7:e1000267; PMID:20422030; http://dx.doi.org/10.1371/journal.pmed.1000267
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923
5. Hartwig W, Werner J, Jager D, Debus J, Buchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol 2013; 14:e476-85; PMID:24079875; http://dx.doi.org/10.1016/S1470-4241(13)70142-4

6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22628128; http://dx.doi.org/10.1056/NEJMoa1200694

7. Royal LE, Levy C, Turner K, Mathur A, Hughes M, Kammla US, Sherry RM, Topalian SL, Yang JC, Bowy I et al. Phase 2 trial of a novel agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi.org/10.1097/CJI.0b013e3181f1e64c

8. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Hartwig W, Werner J, Jager D, Debus J, Buchler MW. Improvement of CD8(+) tumor-reactive repertoire in infiltrating human tumors. J Clin Invest 2015; 133:1235-33; PMID:25584002; http://dx.doi.org/10.1172/JCI80031

9. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett GM, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L. Mutations in human gastrointestinal cancers. Science 2015; 350:1387-92; PMID:26290180; http://dx.doi.org/10.1126/science.aaa4971

10. Whatcott CJ, Han H, Von Hoff DD. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction. Cancer J 2015; 21:299-306; PMID:26222082; http://dx.doi.org/10.1097/PP.O00000000000140

11. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Solt S, Dorman A, Wamwea Yager A et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2:616-31; PMID:24942756; http://dx.doi.org/10.1158/2326-6066.CIR-13-0062

12. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011; 254:311-9; PMID:21606835; http://dx.doi.org/10.1097/SLA.0b013e3181f7f21f

13. Halama N, Michel S, Kloor M, Zoernig I, Spille A, Westphal K, Schirmacher P, Jaeger D, Diekmann J, Boegel S, Schrager K, Huttner J. Estimation of immune cell densities in immune cell conglomerates: an approach for high-throughput quantification. PLoS One 2009; 4:e7847; PMID:19242991; http://dx.doi.org/10.1371/journal.pone.0007847

14. Neesse A, Algel H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut 2015; 64:1476-84; PMID:25994217; http://dx.doi.org/10.1136/gutjnl-2015-309304
epithelial cancer. Science 2014; 344:641-5; PMID:24812403; http://dx.doi.org/10.1126/science.1251102

35. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T-cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol 2014; 14:377-91; PMID:24830344; http://dx.doi.org/10.1038/nri3667

36. Amedei A, Niccolai E, Benagiano M, Della Bella C, Gianchì F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello M, P. et al. Ex vivo analysis of pancreatic cancer patients: what thymocytes see. Cancer Immunol Immunother 2013; 62:1249-60; PMID:23640603; http://dx.doi.org/10.1007/s00262-013-1429-3

37. Suso EM, Dulong S, Rasmussen AM, Vetvhus T, Aamdal S, Kvalheim G, Gaudernack G. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011; 60:809-18; PMID:21365467; http://dx.doi.org/10.1007/s00262-011-0991-9

38. Lauwen MM, Zwaalving S, de Quartel L, Ferreira Mota SC, Grashorn JJF, Chin-Aleong J, Chelala C, Gribben JG et al. Activated pancreatic stellate cells sequester CD8+ T-cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013; 145:1121-32; PMID:23891972; http://dx.doi.org/10.1053/j.gastro.2013.07.025

39. Ino Y, Yamazaki-Itoh R, Shimada K, Taddei A, Bencini L, Farsi M, Cappello P et al. Ex vivo analysis of pancreatic cancer patients: what thymocytes see. Nat Rev Immunol 2014; 14:377-91; PMID:24830344; http://dx.doi.org/10.1038/nri3667

40. Ene-Obong A, Clear AJ, Watt J, Wang J, Fatih R, Riches JC, Marshall JF, Chin-Aleong J, Chelala C, Gribben JG et al. Activated pancreatic stellate cells sequester CD8+ T-cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology 2013; 145:1121-32; PMID:23891972; http://dx.doi.org/10.1053/j.gastro.2013.07.025

41. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuki M, Nakakubo Y et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 2004; 28:26-31; PMID:14707745; http://dx.doi.org/10.1097/00006676-200401000-00023

42. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory T-cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34; PMID:17000676; http://dx.doi.org/10.1158/1078-0432.CCR-06-0369

43. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876

44. Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumor tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer 2015; 112:1782-90; PMID:25942397; http://dx.doi.org/10.1038/bjc.2015.145

45. Castino GF, Cortese N, Capretti G, Serio S, Di Caro G, Mineri R, Magrini E, Grizzi F, Cappello P, Novelli F et al. Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology 2016; 5:e1085147; PMID:27141376; http://dx.doi.org/10.1080/2162402X.2015.1085147

46. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, Mulé J. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol 2011; 179:37-45; PMID:21703392; http://dx.doi.org/10.1016/j.ajpath.2011.03.007

47. Dieu-Noxovane MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi.org/10.1200/JCO.2007.15.0284

48. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournier JJ, Rochaix P, Girard JP. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71:5678-87; PMID:21846823; http://dx.doi.org/10.1158/0008-5472.CAN-11-0431

49. Snyder A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med 2015; 372:783; PMID:25693024; http://dx.doi.org/10.1056/NEJMc1415938

50. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Poppen MH, Goldinger SM et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350:207-11; PMID:26359337; http://dx.doi.org/10.1126/science.aad0905

51. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero Ol et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013; 110:20212-7; PMID:24277834; http://dx.doi.org/10.1073/pnas.1320318110

52. Hartmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Britten CM, Kreiter S, T€ureci O, Sahin U. Translation of oncogene-directed immunotherapies to the bedside. Br J Cancer 2014; 111:1469-75; PMID:25314223; http://dx.doi.org/10.1038/bjc.2013.820